Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 12, 2014 16:01 ET | Source: Fate Therapeutics, Inc.

Fate Therapeutics Reports Second Quarter 2014 Financial Results

First Data Review in Phase 2 PUMA Study of PROHEMA Supports Continuation of Enrollment PROMPT and PROVIDE Studies of PROHEMA in Pediatric Patients to Initiate in 2H14 SAN DIEGO, Aug. 12, 2014...
August 05, 2014 07:01 ET | Source: Fate Therapeutics, Inc.

Fate Therapeutics to Webcast Conference Call Reporting Second Quarter 2014 Financial Results on August 12, 2014

SAN DIEGO, Aug. 5, 2014 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (Nasdaq:FATE), a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators to treat orphan...
July 31, 2014 16:01 ET | Source: Fate Therapeutics, Inc.

Fate Therapeutics Secures Up to $20 Million in Debt Financing

SAN DIEGO, July 31, 2014 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (Nasdaq:FATE), a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators to treat orphan...
July 29, 2014 16:01 ET | Source: Fate Therapeutics, Inc.

Fate Therapeutics Announces FDA Clearance of IND for Clinical Development of PROHEMA in Inherited Metabolic Disorders

SAN DIEGO, July 29, 2014 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (Nasdaq:FATE), a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators to treat orphan...
June 30, 2014 16:01 ET | Source: Fate Therapeutics, Inc.

Fate Therapeutics Submits IND Application for the Clinical Development of PROHEMA(R) in Inherited Metabolic Disorders

SAN DIEGO, June 30, 2014 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (Nasdaq:FATE), a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators to treat orphan...
June 05, 2014 07:01 ET | Source: Fate Therapeutics, Inc.

Fate Therapeutics to Highlight Potential Clinical Applications of Ex Vivo Hematopoietic Cell Modulation at 12th International Cord Blood Symposium

SAN DIEGO, June 5, 2014 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (Nasdaq:FATE), a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators to treat orphan...
May 28, 2014 07:00 ET | Source: Fate Therapeutics, Inc.

Fate Therapeutics to Present at Jefferies 2014 Global Healthcare Conference

SAN DIEGO, May 28, 2014 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (Nasdaq:FATE), a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators to treat orphan...
May 13, 2014 16:01 ET | Source: Fate Therapeutics, Inc.

Fate Therapeutics Reports First Quarter 2014 Financial Results

Phase 2 PUMA Study of PROHEMA® in Adult Hematologic Malignancies Enrolling Patients Phase 1b PROMPT Study of PROHEMA in Pediatric Hematologic Malignancies Cleared by FDA IND Submission for...
May 06, 2014 07:00 ET | Source: Fate Therapeutics, Inc.

Fate Therapeutics to Webcast Conference Call Reporting First Quarter 2014 Financial Results on May 13, 2014

SAN DIEGO, May 6, 2014 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (Nasdaq:FATE), a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators to treat orphan...
April 30, 2014 07:00 ET | Source: Fate Therapeutics, Inc.

Fate Therapeutics to Present at Deutsche Bank 39th Annual Health Care Conference

SAN DIEGO, April 30, 2014 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (Nasdaq:FATE), a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators to treat orphan...